Download PDF

1. Company Snapshot

1.a. Company Description

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain.The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.It is also involved in developing various research programs for other neurological diseases.


The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University.Inhibikase Therapeutics, Inc.was founded in 2008 and is headquartered in Atlanta, Georgia.

Show Full description

1.b. Last Insights on IKT

Inhibikase Therapeutics' recent performance has been driven by a consensus "Buy" rating from analysts, with three strong buy recommendations and one sell recommendation. This positive sentiment is reflected in the company's strong profitability, valuation, and earnings, as well as its favorable institutional ownership and dividend profile. The company's recent public offering of $100 million in common stock and pre-funded warrants has also provided a boost to its financial position. Additionally, the company's focus on developing therapeutics for pulmonary arterial hypertension has the potential to drive growth and increase its market share.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Analyzing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)

Feb -18

Source: defenseworld.net

Card image cap

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of “Buy” from Analysts

Feb -15

Source: defenseworld.net

Card image cap

Comparing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)

Feb -06

Source: defenseworld.net

Card image cap

Comparing Liminatus Pharma (NASDAQ:LIMN) & Inhibikase Therapeutics (NASDAQ:IKT)

Jan -04

Source: defenseworld.net

Card image cap

Liminatus Pharma (NASDAQ:LIMN) vs. Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Contrast

Dec -28

Source: defenseworld.net

Card image cap

Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Survey

Dec -27

Source: defenseworld.net

Card image cap

Critical Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus Liminatus Pharma (NASDAQ:LIMN)

Dec -26

Source: defenseworld.net

Card image cap

Analyzing Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT)

Dec -21

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Protein Kinase Inhibitor Therapeutics

Expected Growth: 10.2%

Growing prevalence of neurodegenerative diseases, increasing demand for novel treatments, and advancements in kinase signaling research drive the growth of Protein Kinase Inhibitor Therapeutics market.

7. Detailed Products

IKT-001

IKT-001 is a novel, orally administered, small molecule inhibitor of c-Abl, a key enzyme involved in the regulation of Abelson tyrosine-protein kinase 1 (c-Abl) and its oncogenic variant, BCR-Abl.

IKT-02

IKT-02 is a novel, orally administered, small molecule inhibitor of c-Abl and its oncogenic variant, BCR-Abl, with improved potency and selectivity.

IKT-03

IKT-03 is a novel, orally administered, small molecule inhibitor of c-Abl and its oncogenic variant, BCR-Abl, with enhanced CNS penetration.

8. Inhibikase Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Inhibikase Therapeutics, Inc. operates in a niche market with limited substitutes, reducing the threat of substitutes.

Bargaining Power Of Customers

The company's customers are primarily pharmaceutical companies, which have limited bargaining power due to the specialized nature of Inhibikase's products.

Bargaining Power Of Suppliers

Inhibikase Therapeutics, Inc. relies on a few key suppliers for raw materials, giving them some bargaining power, but the company's specialized products limit their negotiating power.

Threat Of New Entrants

The biotechnology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise, making it difficult for new entrants to compete with Inhibikase Therapeutics, Inc.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established players and new entrants vying for market share, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 5.36%
Debt Cost 3.95%
Equity Weight 94.64%
Equity Cost 10.53%
WACC 10.18%
Leverage 5.67%

11. Quality Control: Inhibikase Therapeutics, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Eyenovia

A-Score: 3.7/10

Value: 8.0

Growth: 4.7

Quality: 3.3

Yield: 0.0

Momentum: 6.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Gritstone bio

A-Score: 3.7/10

Value: 8.8

Growth: 4.7

Quality: 2.5

Yield: 0.0

Momentum: 6.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
HCW Biologics

A-Score: 2.9/10

Value: 8.2

Growth: 4.2

Quality: 4.9

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Cardio Diagnostics Holdings

A-Score: 2.9/10

Value: 8.0

Growth: 4.1

Quality: 3.2

Yield: 0.0

Momentum: 1.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Omega Therapeutics

A-Score: 2.6/10

Value: 9.0

Growth: 3.6

Quality: 2.5

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Inhibikase Therapeutics

A-Score: 2.4/10

Value: 6.9

Growth: 3.2

Quality: 2.4

Yield: 0.0

Momentum: 1.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.76$

Current Price

1.76$

Potential

-0.00%

Expected Cash-Flows